
Venture firm investing in software and hardware startups for architecture, engineering and construction

Life sciences venture firm investing in early-stage treatments and diagnostics for rare diseases

Focused on rare and orphan disorders, Chiesi Ventures is a life science investor. It invests in early stage development opportunities that complement the strategic interests of the Chiesi Group, and it aims to widen the Chiesi network in Europe and the United States, among universities, investors, rare disease patient groups and entrepreneurial companies developing treatments.
The firm looks across classic small molecules, biologics, drug formulation and medical devices, and disease discovery, diagnosis and management. It describes its focus as improving the quality of diagnosis, disease management, care and therapy for everyone affected by a rare disease. It is building a portfolio of companies focused on rare diseases, each with complementary capabilities and missions.
According to the firm, rare diseases are conditions affecting fewer than 200,000 people in the United States, and fewer than five in 10,000 people under the definition adopted by the European Medicines Agency. It says an estimated six to seven thousand rare diseases have been diagnosed so far, and that around thirty million people in Europe are affected by one, with a similar number in the United States. It adds that most rare diseases are genetic in nature, and it describes a goal of a society where diagnosis takes days rather than years.
In 2014 Chiesi Ventures announced a strategic collaboration with A. M. Pappas & Associates, a partner the company credits with widening its reach into deals and with helping it lead and run transactions. The firm says rare diseases are global in nature, from diagnosis through to clinical development, and so it set up offices in Italy and the United States to evaluate opportunities and assist companies in both the US and the EU.
The firm says it wants to be instrumental in funding research and development opportunities for therapies that can offer hope to patients and their families. It believes rare diseases give it a chance to build a path that is worthwhile and beneficial to society, and it works with researchers, the scientific community, industry and regulators to pursue that aim.
Chiesi Ventures is a life sciences venture capital firm dedicated to rare and orphan disorders. It complements the strategic interests of the Chiesi Group by investing in early-stage development opportunities.
Companies developing treatments for rare diseases. In September 2014 it announced a collaboration with Pappas Capital to help find and assess deals, lead investments and manage transactions.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Chiesi Ventures.
Similar listings buyers compare against this one.

Venture firm investing in software and hardware startups for architecture, engineering and construction

StarLaunch is a launchpad and incubator for blockchain projects, mainly on the Solana network

Life sciences venture fund backing biotech and biopharma companies from seed to later stage across three regions

Commodity intelligence platform giving food and beverage buyers price data and forecasts

Seed-stage venture capital firm backing technology and consumer packaged goods startups with a sustainability focus

A life sciences venture fund investing in biotechnology and biopharma companies across multiple stages

Pharmaceutical group's partnering and venture investment arm working with outside biotech innovators

Northern Ireland's economic development agency supporting start-ups, exporters and growing local businesses
Everything here links back to the same verified catalogue. Pick your next stop.